Ketoheterocycle-based inhibitors of cathepsin K: A novel entry into the synthesis of peptidic ketoheterocycles

被引:17
作者
Tavares, FX [1 ]
Deaton, DN
Miller, AB
Miller, LR
Wright, LL
机构
[1] GlaxoSmithKline Inc, Dept Med Chem, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline Inc, Discovery Res Computat Analyt & Struct Sci, Res Triangle Pk, NC 27709 USA
[3] GlaxoSmithKline Inc, Dept Mol Pharmacol, Res Triangle Pk, NC 27709 USA
[4] GlaxoSmithKline Inc, Discovery Res Biol, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1016/j.bmcl.2005.05.091
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ketoheterocyclic inhibitors of cathepsin K have been disclosed. SAR of potency enhancing P-2-P-3 groups coupled with ketoheterocyclic warheads to provide cathepsin K inhibitors have been described. In addition, a novel route to access alpha-ketothiazoles using a key thioamide functionality has been disclosed. The mild method employed allows for the presence of diverse functional groups, such as amide and carbamate functionalities, commonly found in protease inhibitors that have peptidomimetic scaffolds. This new method should provide a quick entry into functionally diverse protease inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3891 / 3895
页数:5
相关论文
共 24 条
[1]   Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1′, P1, and/or P3 substitutions [J].
Barrett, DG ;
Catalano, JG ;
Deaton, DN ;
Hassell, AM ;
Long, ST ;
Miller, AB ;
Miller, LR ;
Shewchuk, LM ;
Wells-Knecht, KJ ;
Willard, DH ;
Wright, LL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (19) :4897-4902
[2]   Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K [J].
Barrett, DG ;
Catalano, JG ;
Deaton, DN ;
Long, ST ;
Miller, LR ;
Tavares, FX ;
Wells-Knecht, KJ ;
Wright, LL ;
Zhou, HQQ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (10) :2543-2546
[3]   Exploration of the P2-P3SAR of aldehyde cathepsin K inhibitors [J].
Boros, EE ;
Deaton, DN ;
Hassell, AM ;
McFadyen, RB ;
Miller, AB ;
Miller, LR ;
Paulick, MG ;
Shewchuk, LM ;
Thompson, JB ;
Willard, DH ;
Wright, LL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (13) :3425-3429
[4]   Cathepsin K inhibitors, 2000-2004 [J].
Cai, JQ ;
Jamieson, C ;
Moir, J ;
Rankovic, Z .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (01) :33-48
[5]   Design of small molecule ketoamide-based inhibitors of cathepsin K [J].
Catalano, JG ;
Deaton, DN ;
Long, ST ;
McFadyen, RB ;
Miller, LR ;
Payne, JA ;
Wells-Knecht, KJ ;
Wright, LL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (03) :719-722
[6]   Exploration of the P1SAR of aldehyde cathepsin K inhibitors [J].
Catalano, JG ;
Deaton, DN ;
Furfine, ES ;
Hassell, AM ;
McFadyen, RB ;
Miller, AB ;
Miller, LR ;
Shewchuk, LM ;
Willard, DH ;
Wright, LL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) :275-278
[7]   Potent thrombin inhibitors that probe the S-1' subsite: Tripeptide transition state analogues based on a heterocycle-activated carbonyl group [J].
Costanzo, MJ ;
Maryanoff, BE ;
Hecker, LR ;
Schott, MR ;
Yabut, SC ;
Zhang, HC ;
AndradeGordon, P ;
Kauffman, JA ;
Lewis, JM ;
Krishnan, R ;
Tulinsky, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (16) :3039-3043
[8]   Novel and potent cyclic cyanamide-based cathepsin K inhibitors [J].
Deaton, DN ;
Hassell, AM ;
McFadyen, RB ;
Miller, AB ;
Miller, LR ;
Shewchuk, LM ;
Tavares, FX ;
Willard, DH ;
Wright, LL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (07) :1815-1819
[9]  
Deaton DN, 2004, PROGR MED CHEM, V42, P245, DOI 10.1016/S0079-6468(04)42006-2
[10]   Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts [J].
Drake, FH ;
Dodds, RA ;
James, IE ;
Connor, JR ;
Debouck, C ;
Richardson, S ;
LeeRykaczewski, E ;
Coleman, L ;
Rieman, D ;
Barthlow, R ;
Hastings, G ;
Gowen, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12511-12516